The drug maker said that the US drug regulator has issued Form 483, with five observations after inspecting its subsidiary’s formulations (oncology) manufacturing facility at Baddi, Himachal Pradesh.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
